At DJS we are developing novel therapeutics to treat chronic inflammatory diseases. We do this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. Our breakthrough technology enables us to produce first-in-class antibody therapeutics to previously intractable disease targets.
Employees: 1-10
Total raised: $8.039468M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | MassChalle... | masschalle... |
| - | Oxford Sci... | oxfordscie... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.12.2020 | - | $8.039468M | LifeArc |
Mentions in press and media 4
| Date | Title | Description | Source |
| 20.10.2022 | AbbVie acquires LifeArc portfolio company DJS Antibodies | AbbVie (NYSE: ABBV) has acquired LifeArc’s portfolio company DJS Antibodies Limited (“DJS”), a priva... | lifearc.or... |
| 22.12.2020 | LifeArc co-leads £6 million funding in DJS Antibodies | LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company p... | lifearc.or... |
| 22.12.2020 | LifeArc co-leads £6 million funding in DJS Antibodies | LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company p... | lifearcven... |
| - | AbbVie acquires LifeArc portfolio company DJS Antibodies | AbbVie (NYSE: ABBV) has acquired LifeArc’s portfolio company DJS Antibodies Limited (“DJS”), a priva... | lifearcven... |